Biogen's controversial Alzheimer’s drug generates $2 million in first few weeks after approval
July 22, 2021 at 07:56 AM EDT
Biogen's Alzheimer's drug, Adhulem, generated $2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.
